In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are used in the collection, preparation, and examination of specimens taken from the human body. This includes Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers, Oncology and Reproductive Health Diagnostics. Kirsten Rat Sarcoma Virus (KRAS) gene tests are carried out to detect gene mutations in patient tissue samples; the outcome of which may guide therapies to treat various cancers including Colorectal Cancer (CRC), certain lung cancers, and some leukemias. GlobalData uses proprietary data and analytics to provide a comprehensive report on the kras tests market in Italy. Buy the latest report here.
Smarter leaders trust GlobalData
In 2023, GlobalData’s Market Model methodology determined that the leading player in the kras tests market in Italy was Qiagen followed by Mesa Laboratories, F. Hoffmann-La Roche, Abbott Laboratories, NimaGen, Biocartis Group, Sysmex, EntroGen and Amoy Diagnostics.
Understanding market size can be crucial to evaluate opportunities and make informed decisions about market entry and exit. Medical device companies can identify attractive segments in respective markets as well as develop marketing strategies based on forecasts for those segments.
CRC is classified based on the stage of the disease at diagnosis. CRC has been divided into localized, regional metastasis, and distant metastasis. Localized CRC is defined as cancer that has not yet metastasized. Regional metastasis refers to cancer that has spread to the lymph nodes near the colon or rectum. Distant metastasis refers to cancer that has spread to other organs of the body such as the lungs. There are two other widely used systems to classify CRC. The first groups CRC into stages -IV and the second use a lettering system (A-D). GlobalData considers stage -II & A-B as localized, stage III & stage C as regional metastasis, and stage IV & stage D as distant metastasis. The KRAS Tests includes Colorectal Cancer Stages of Diagnosis, KRAS Sanger Sequencing Tests; KRAS Nucleic Acid Amplification Tests (NAATs), and KRAS Other Tests comprises of In Situ Hybridisation (ISH) and Mass Array.
The kras tests market in Italy can expand or contract due to a variety of reasons including population demographics, disease incidence and prevalence, macroeconomic issues, and geopolitical considerations. Disruption to a market could be caused by a sudden, unexpected change in these factors, but it could also be driven by changes in clinical practice, leading to a change in diagnosis or treatment of patients, as part of a process to generally improve medical practice.
For the latest analysis of the market size kras tests in Italy, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Medical Intelligence Center Market Models are the gold standard of medical device market valuation, company share estimation and market trend forecasting. GlobalData uses a patient-based forecast model or installed base methodology to determine the market size for therapeutic indications and capital equipment expenditures. Estimates are based on a number of sources, including primary research—KOL and industry contact interviews—and secondary research, such as company reports, press releases, published articles, proprietary databases, and general news media.
